News headlines about Egalet Corporation (NASDAQ:EGLT) have been trending somewhat positive on Tuesday, Accern Sentiment reports. The research group rates the sentiment of press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Egalet Corporation earned a daily sentiment score of 0.08 on Accern’s scale. Accern also gave news coverage about the specialty pharmaceutical company an impact score of 46.6126842445708 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Here are some of the news articles that may have effected Accern’s analysis:

A number of equities research analysts recently weighed in on EGLT shares. Cantor Fitzgerald reissued a “buy” rating and set a $8.00 target price on shares of Egalet Corporation in a research report on Thursday, June 1st. Zacks Investment Research raised Egalet Corporation from a “hold” rating to a “buy” rating and set a $3.50 price objective on the stock in a report on Tuesday, May 9th. ValuEngine downgraded Egalet Corporation from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. Gabelli raised Egalet Corporation from a “hold” rating to a “buy” rating and set a $9.50 price objective on the stock in a report on Friday, May 12th. They noted that the move was a valuation call. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $6.00 price objective (down from $14.00) on shares of Egalet Corporation in a report on Thursday, August 10th. One analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $6.50.

Shares of Egalet Corporation (EGLT) opened at 1.12 on Tuesday. Egalet Corporation has a 12-month low of $1.01 and a 12-month high of $10.00. The firm’s market capitalization is $48.21 million. The firm’s 50-day moving average price is $1.56 and its 200-day moving average price is $3.33.

Egalet Corporation (NASDAQ:EGLT) last announced its earnings results on Wednesday, August 9th. The specialty pharmaceutical company reported ($1.04) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.94) by $0.10. Egalet Corporation had a negative return on equity of 2,190.07% and a negative net margin of 444.50%. The business had revenue of $6.26 million for the quarter, compared to analyst estimates of $6.68 million. During the same quarter in the previous year, the company earned ($0.97) EPS. The business’s revenue for the quarter was up 81.4% on a year-over-year basis. Equities analysts predict that Egalet Corporation will post ($2.72) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece of content was reported by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark laws. The legal version of this piece of content can be accessed at https://www.watchlistnews.com/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-egalet-corporation-eglt-share-price/1488349.html.

Egalet Corporation Company Profile

Egalet Corporation is a specialty pharmaceutical company. The Company is engaged in developing, manufacturing and commercializing treatments for pain and other conditions. The Company’s products include OXAYDO and SPRIX Nasal Spray. The Company is developing two late-stage product candidates, ARYMO ER and Egalet-002 using Guardian Technology.

Insider Buying and Selling by Quarter for Egalet Corporation (NASDAQ:EGLT)

Receive News & Ratings for Egalet Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Egalet Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.